$0.69
1.61% yesterday
Nasdaq, Nov 25, 10:01 pm CET
ISIN
US92536C1036
Symbol
VERU

Veru Inc Stock price

$0.69
-0.15 17.58% 1M
-0.54 44.24% 6M
-0.03 4.74% YTD
-0.31 31.20% 1Y
-7.20 91.31% 3Y
-1.43 67.65% 5Y
-3.68 84.30% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.01 1.61%
ISIN
US92536C1036
Symbol
VERU

Key metrics

Market capitalization $100.40m
Enterprise Value $84.93m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.03
P/S ratio (TTM) P/S ratio 7.13
P/B ratio (TTM) P/B ratio 2.67
Revenue growth (TTM) Revenue growth -6.20%
Revenue (TTM) Revenue $14.09m
EBIT (operating result TTM) EBIT $-41.64m
Free Cash Flow (TTM) Free Cash Flow $-27.12m
Cash position $29.15m
EPS (TTM) EPS $-0.34
P/E forward negative
P/S forward 7.30
EV/Sales forward 6.18
Short interest 9.47%
Show more

Is Veru Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Veru Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Veru Inc forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a Veru Inc forecast:

Buy
80%
Hold
20%

Financial data from Veru Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
14 14
6% 6%
100%
- Direct Costs 9.40 9.40
10% 10%
67%
4.69 4.69
27% 27%
33%
- Selling and Administrative Expenses 30 30
52% 52%
212%
- Research and Development Expense 16 16
77% 77%
115%
-41 -41
68% 68%
-294%
- Depreciation and Amortization 0.27 0.27
67% 67%
2%
EBIT (Operating Income) EBIT -42 -42
68% 68%
-296%
Net Profit -40 -40
67% 67%
-285%

In millions USD.

Don't miss a Thing! We will send you all news about Veru Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Veru Inc Stock News

Neutral
GlobeNewsWire
21 days ago
MIAMI, FL, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from a meta-analysis presentation at ObesityWeek, which took place November 5, 2024, in San Anton...
Neutral
GlobeNewsWire
about one month ago
MIAMI, FL, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present at ObesityWeek, taking place November 3-6, 2024, in San Antonio, Texas.
Neutral
GlobeNewsWire
about one month ago
MIAMI, FL, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present at the World Obesity and Weight Management Congress, taking place Octobe...
More Veru Inc News

Company Profile

Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company's urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL.

Head office United States
CEO Mitchell Steiner
Founded 1971
Website www.verupharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today